ipilimumab
bms
['m14til', 'ipilimumab', 'melanoma']
a tumor-infiltrating lymphocyte therapy showed a 50% reduction in the risk of disease progression or death compared with ipilimumab in stage iiic/iv unresectable, treatment-refractory melanoma, according to findings from the m14til trial. #esmo2022 
Oncology news and insights from leading researchers and cancer centers.